Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.

Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles

Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.

She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.

2400, avenue d'Estimauville
3e étage
U-3130
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6368+1 418-666-2776
chantal.sauvageau@crchude... chantal.sauvageau@inspq.q...

Latest news

118 entries « ‹ 2 of 12 › »

Chambers C, Deeks SL, Sutradhar R, Cox J, de Pokomandy A, Grennan T, Hart TA, Lambert G, Moore DM, Grace D, Grewal R, Jollimore J, Lachowsky N, Nisenbaum R, Ogilvie G, Sauvageau C, Tan DHS, Coutlée F, Burchell AN

Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men

Journal Article

J Infect Dis, 228 (1), 2023.

Abstract | Links:

Ionescu IG, Skowronski DM, Sauvageau C, Chuang E, Ouakki M, Kim S, De Serres G

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration

Journal Article

J Infect Dis, 227 (9), 2023.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Journal Article

Lancet Infect Dis, 23 (1), 2023.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Sauvageau C, Brousseau N, Gilca R, Ouakki M, Barkati S, Fafard J, Talbot D, Gilca V, Deceuninck G, Garenc C, Carignan A, De Wals P, De Serres G

Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada

Journal Article

JAMA Netw Open, 5 (10), 2022.

Abstract | Links:

Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada

Journal Article

Clin Infect Dis, 75 (11), 2022.

Abstract | Links:

Fortin É, De Wals P, Talbot D, Ouakki M, Deceuninck G, Sauvageau C, Gilca R, Kiely M, De Serres G

Impact of the first vaccine dose on COVID-19 and its complications in long-term care facilities and private residences for seniors in Québec, Canada

Journal Article

Can Commun Dis Rep, 48 (4), 2022.

Abstract | Links:

Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin É, Carignan A, De Wals P, Skowronski DM, De Serres G

Single-Dose Messenger RNA Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Workers Extending 16 Weeks Postvaccination: A Test-Negative Design From Québec, Canada

Journal Article

Clin Infect Dis, 75 (1), 2022.

Abstract | Links:

Chambers C, Deeks SL, Sutradhar R, Cox J, de Pokomandy A, Grennan T, Hart TA, Lambert G, Moore DM, Coutlée F, Grace D, Grewal R, Jollimore J, Lachowsky N, Nisenbaum R, Ogilvie G, Sauvageau C, Tan DHS, Burchell AN

Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada

Journal Article

Vaccine, 40 (26), 2022.

Abstract | Links:

Sauvageau C, Amini R, Gilca V, Derhy E, Charland Larivière S, Desbiens M, Dubois G, Gagnon Labelle K, Gilbert S

Fardeau de la varicelle et du zona à la suite de l’introduction du programme de vaccination contre la varicelle à une puis à deux doses au Québec

Book

Institut national de santé publique du Québec, Québec, QC, 2022, ISBN: 9782550914303.

| Links:

Drolet M, Godbout A, Mondor M, Béraud G, Drolet-Roy L, Lemieux-Mellouki P, Bureau A, Demers É, Boily MC, Sauvageau C, De Serres G, Hens N, Beutels P, Dervaux B, Brisson M

Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study

Journal Article

BMC Public Health, 22 (1), 2022.

Abstract | Links:

118 entries « ‹ 2 of 12 › »
Signaler des ajouts ou des modifications

Active projects

  • Analyser les effets de la pandémie de COVID-19 sur l'utilisation communautaire des antibiotiques en fonction de la multimorbidité et rechercher des opportunités d'intervention contre l'antibioresistance, from 2023-05-29 to 2025-05-31
  • Durée de l'efficacité d'un calendrier de vaccination à deux doses contre les VPH et la plus-value d'une dose de rappel : diffusion des résultats clés de l'étude ICI-VPH pour soutenir la prise de décision, from 2022-02-02 to 2026-03-31
  • Optimization of HPV vaccination and screening in Canada, considering opportunities provided by 1-dose vaccination: A mathematical modeling study, from 2023-04-01 to 2025-03-31
  • Optimizing HPV vaccination programs in Low- and Middle-Income Countries (LMIC) and Canada to reduce inequalities and reach global elimination of cervical cancer: An integrated knowledge translation dynamic-modeling approach, from 2024-10-01 to 2028-09-30
  • Optimizing HPV vaccination programs in Low- and Middle-Income Countries (LMIC) and High-Income Countries (HIC) to reduce inequalities and reach global elimination of cervical cancer: An integrated knowledge translation dynamic-modeling, from 2024-03-01 to 2025-02-28

Recently finished projects

  • Essai clinique visant à documenter l’immunogénicité d’une dose de GARDASILMD ou GARDASIL 9MD et l’effet d’une dose du vaccin GARDASIL 9MD ou CERVARIXMD administré 3 ans et plus après la première dose, from 2023-10-13 to 2024-06-30
  • HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
Data provided by the Université Laval research projects registery